1. Home
  2. ESNT vs IONS Comparison

ESNT vs IONS Comparison

Compare ESNT & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Essent Group Ltd.

ESNT

Essent Group Ltd.

SELL

Current Price

$64.81

Market Cap

6.0B

Sector

Finance

ML Signal

SELL

Logo Ionis Pharmaceuticals Inc.

IONS

Ionis Pharmaceuticals Inc.

HOLD

Current Price

$28.38

Market Cap

6.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESNT
IONS
Founded
2008
1989
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
6.6B
IPO Year
2013
1996

Fundamental Metrics

Financial Performance
Metric
ESNT
IONS
Price
$64.81
$28.38
Analyst Decision
Buy
Buy
Analyst Count
9
25
Target Price
★ $70.88
$68.48
AVG Volume (30 Days)
711.3K
★ 4.2M
Earning Date
11-06-2026
11-09-2026
Dividend Yield
★ 2.15%
N/A
EPS Growth
0.73
★ 21.71
EPS
★ 5.71
N/A
Revenue
★ $1,260,935,000.00
N/A
Revenue This Year
$15.16
N/A
Revenue Next Year
N/A
$26.34
P/E Ratio
$11.43
★ N/A
Revenue Growth
★ 1.45
N/A
52 Week Low
$55.34
$27.25
52 Week High
$71.84
$86.74

Technical Indicators

Market Signals
Indicator
ESNT
IONS
Relative Strength Index (RSI) 47.26 22.61
Support Level $63.62 N/A
Resistance Level $69.21 $46.07
Average True Range (ATR) 1.84 2.07
MACD -0.31 -1.18
Stochastic Oscillator 22.70 7.56

Price Performance

Historical Comparison
ESNT
IONS

About ESNT Essent Group Ltd.

Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Share on Social Networks: